Thyroid-Induced Toxicity of Check-Point Inhibitors Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

Gridelli, Cesare

doi:10.15226/2374-6890/3/1/00143

Cited by 7 publications

(10 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the CTLA-4 molecule, which regulates the activation of T lymphocytes at an early stage of the immune response, inhibiting their autoreactivity within the lymph nodes, in the case of an immune response involving PD-1 molecules, this inhibition occurs in peripheral tissue or in the tumor microenvironment [9].…”

Section: Inhibitory Molecules and Their Use In Oncologymentioning

confidence: 99%

“…Currently used immune checkpoint inhibitors (ICI), apart from ipilimumab, include the anti-PD-1 antibodies nivolumab and pembrolizumab and anti-PD-L1 antibodies atezolizumab, durvalumab and avelumab [9]. Antibodies that attach to the PD-1 receptor block the interaction between PD-1 and its ligands PD-L1 and PD-L2 and inhibit the signaling pathway by preventing tumor-derived PD-L1 from blocking T lymphocytes [13].…”

Section: Inhibitory Molecules and Their Use In Oncologymentioning

confidence: 99%

“…The frequency of significant adverse effects of nivolumab with a possible immune mechanism is estimated at 10-20% of patients undergoing immunotherapy [27], of which endocrine adverse events range from 2-8% [9,28] up to 23% [29]. Table 1 lists the frequency of endocrine AE of nivolumab with a possible immune background (data based on the analysis of 1994 patients receiving nivolumab monotherapy for all registered indications) [30].…”

Section: Adverse Events Associated With Anti-pd-1 and Anti-pd-l1 Immumentioning

confidence: 99%

“…In some studies, thyroid antibodies were present in the majority of patients with abnormal thyroid function in the course of anti-PD-1 treatment [70]. However, there have also been studies in which the presence of the antibodies was not common [19,58,73,80]; for example, in the study by Gridelli, a lack of antibodies was found even in one third of the patients [9], and according to Peiró's analysis, autoimmunity was found only in one third of patients with thyroid disorders due to nivolumab treatment [72]. These observations suggest a complex mechanism of irAE in the thyroid, including an antibody-independent mechanism of cellular response or the role of other thyroid antibodies which are not evaluated routinely.…”

Section: Mechanismsmentioning

confidence: 99%

“…Normalization of thyroid function was observed in 76% of patients [13,30]. It seems that, in patients with NSCLC in whom chronic TSH decline is observed and there are mild symptoms of subclinical hyperthyroidism, anti-thyroid drug administration could be beneficial [9].…”

Section: Management Of Adverse Events During Nivolumab Treatmentmentioning

confidence: 99%

See 4 more Smart Citations

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

Dudzińska

Szczyrek

Wojas‐Krawczyk

et al. 2020

Cancers

View full text Add to dashboard Cite

In recent years, we have observed significant progress in cancer treatment associated with the development of immunotherapy. A programmed cell death 1 molecule (PD-1) on the surface of T lymphocytes may be stimulated via a specific PD-ligand 1 (PD-L1), which inhibits lymphocyte activation and leads to apoptosis. Some malignant cells are characterized by high PD-L1 expression. Nivolumab, an anti-PD-1 antibody, blocks the interaction between PD-1 and its ligands and inhibits the signaling pathway by preventing the tumor-derived PD-L1 from blocking T lymphocytes. In patients with non-small cell lung cancer (NSCLC), it is used either in monotherapy or in combination with other drugs. Immunotherapy is associated with the possibility of immune-related adverse effects (irAE) including endocrinopathies (3–23%). Thyroid disorders are the most common, with severity rarely exceeding grade 2. Hypophysitis, adrenal insufficiency and diabetes are possible complications which require immediate treatment. Individuals with autoimmune diseases diagnosed prior to immunotherapy are at risk of its exacerbation. In the management of patients receiving immunotherapy, evaluation of history of autoimmune diseases, awareness and early diagnosis of irAE are crucial and may affect treatment outcomes.

show abstract

Section: Inhibitory Molecules and Their Use In Oncologymentioning

confidence: 99%

Section: Inhibitory Molecules and Their Use In Oncologymentioning

confidence: 99%

Section: Adverse Events Associated With Anti-pd-1 and Anti-pd-l1 Immumentioning

confidence: 99%

Section: Mechanismsmentioning

confidence: 99%

Section: Management Of Adverse Events During Nivolumab Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

Dudzińska

Szczyrek

Wojas‐Krawczyk

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

A multifunctional long‐term release system for treatment of hypothyroidism

Kaya

Gümrükçü

Saraç

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

Hypothyroidism is an autoimmune disease associated with underactive thyroid gland. In this study, a dual effect polymeric system was designed to release Cepharanthine (CEP) to block T cell activation and Selenium (Se) to decrease the anti-thyroid peroxidase (TPOAb) concentration in order to treat hypothyroidism. For this purpose, poly(ethylenevinyl acetate) (PEVA) and polyethylene glycol (PEG) nanoparticles (NPs) including CEP were synthesized by emulsion solvent evaporation method and they were loaded to polyurethane (PU)/PEG-PUSe-PEG block copolymer blends which were fabricated by particulate leaching technique as porous sponges. Fourier-Transform Infrared (FTIR), Raman, and Nuclear Magnetic Resonance (NMR) analysis showed successful synthesis of PEG-PUSe-PEG block copolymer. A long-term zero-order release profile was obtained for CEP. Se release rate from matrices showed an oxidative stress-mediated release which can be used to adjust Se amount. According to MTS results conducted by NIH 3T3 fibroblasts, both NPs and matrices have no adverse effect on cell viability. Fluorescence microscopy and SEM images confirm the MTS results. The dual release system has potential to be effectively used in long-term treatment of hypothyroidism by addressing both auto-immune response and hormone regulation. K E Y W O R D SCepharanthine, controlled release system, hypothyroidism, selenium, thyroid hormones

show abstract

Endocrinology aspects of other clinical or physiological situations

Brooke¹,

Hirwa²,

Higham³

et al. 2022

Oxford Handbook of Endocrinology &Amp; Diabetes 4e

View full text Add to dashboard Cite

This chapter covers endocrine aspects of a variety of conditions and situations. It explains the symptoms and investigations of hypoglycaemia along with its management; mastocytosis, cancer and the associated endocrine sequalae of survivors of childhood cancer, syndromes of ectopic hormone production, and associated disorders. It then covers the effects on endocrinology on liver and renal diseases, and in the critically ill. Differential diagnosis of endocrine disorders is outlined, alongside the effects of stress and exercise on the endocrine system. Finally, alternative therapies are discussed.

show abstract

Thyroid-Induced Toxicity of Check-Point Inhibitors Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

Cited by 7 publications

References 46 publications

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

A multifunctional long‐term release system for treatment of hypothyroidism

Endocrinology aspects of other clinical or physiological situations

Contact Info

Product

Resources

About